1
|
Bonfiglio F, Bruscaggin A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Pirosa MC, Cittone MG, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista MJ, Bastidas G, Bea S, Boldorini R, Broccoli A, Canzonieri V, Cascione L, Ceriani L, Cogliatti S, Derenzini E, Devizzi L, Dietrich S, Elia AR, Facchetti F, Gaidano G, Garcia JF, Gerber B, Ghia P, Silva MG, Gritti G, Guidetti A, Hitz F, Inghirami G, Ladetto M, Lopez‐Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia A, Mollejo M, Montalban C, Novak U, Oscier DG, Passamonti F, Piazza F, Pizzolitto S, Sabattini E, Salles G, Santambrogio E, Scarfó L, Stathis A, Stüssi G, Geyer JT, Tapia G, Thieblemont C, Tousseyn T, Tucci A, Visco C, Vitolo U, Zenz T, Zinzani PL, Khiabanian H, Calcinotto A, Bertoni F, Bhagat G, Campo E, Leval L, Dirnhofer S, Pileri SA, Piris MÁ, Traverse‐Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D. GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.43_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
2
|
Ferreri AJM, Angelillo P, Erbella F, Liberatore C, Cattaneo C, Verga L, Lleshi A, Allione B, Facchetti F, Ponzoni M, Pagani C, Foppoli M, Pecciarini L, Sassone MC, Flospergher E, Rossi G, Spina M, A. Re. SAFETY AND EFFICACY OF THE “CARMEN” REGIMEN, A NEW DOSE‐DENSE SHORT‐TERM THERAPY IN PATIENTS WITH AGGRESSIVE B‐CELL LYMPHOMA AND
MYC
REARRANGEMENT. Hematol Oncol 2021. [DOI: 10.1002/hon.93_2880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. J. M Ferreri
- IRCCS San Raffaele Scientific Institute Department of Onco‐Hematology Milan Italy
| | - P Angelillo
- IRCCS San Raffaele Scientific Institute Department of Onco‐Hematology Milan Italy
| | - F Erbella
- IRCCS San Raffaele Scientific Institute Department of Onco‐Hematology Milan Italy
| | - C Liberatore
- IRCCS San Raffaele Scientific Institute Department of Onco‐Hematology Milan Italy
| | - C Cattaneo
- Spedali Civili di Brescia UOC Ematologia Brescia Italy
| | - L Verga
- Azienda Ospedaliera San Gerardo Divisione di Ematologia Monza Italy
| | - A Lleshi
- Centro Riferimento Oncologico Oncologia Medica Aviano Italy
| | - B Allione
- AOU Città della Salute e della Scienza di Torino SC Ematologia Torino Italy
| | - F Facchetti
- Spedali Civili di Brescia, Servizio di Anatomia Patologica Brescia Italy
| | - M Ponzoni
- IRCCS San Raffaele Scientific Institute Anatomia Patologica Milan Italy
| | - C Pagani
- Spedali Civili di Brescia UOC Ematologia Brescia Italy
| | - M Foppoli
- IRCCS San Raffaele Scientific Institute Department of Onco‐Hematology Milan Italy
| | - L Pecciarini
- Spedali Civili di Brescia, Servizio di Anatomia Patologica Brescia Italy
| | - M. C Sassone
- IRCCS San Raffaele Scientific Institute Department of Onco‐Hematology Milan Italy
| | - E Flospergher
- IRCCS San Raffaele Scientific Institute Department of Onco‐Hematology Milan Italy
| | - G Rossi
- Spedali Civili di Brescia UOC Ematologia Brescia Italy
| | - M Spina
- IRCCS Centro Riferimento Oncologico SOC Oncologia Medica e Tumori Immunocorrelati Aviano Italy
| | - A. Re
- Spedali Civili di Brescia UOC Ematologia Brescia Italy
| |
Collapse
|
3
|
Di Napoli A, Remotti D, Agostinelli C, Ambrosio MR, Ascani S, Carbone A, Facchetti F, Lazzi S, Leoncini L, Lucioni M, Novero D, Pileri S, Ponzoni M, Sabattini E, Tripodo C, Zamò A, Paulli M, Ruco L. Correction to: A practical algorithmic approach to mature aggressive B cell lymphoma diagnosis in the double/triple hit era: selecting cases, matching clinical benefit. Virchows Arch 2019; 475:799. [PMID: 31664506 DOI: 10.1007/s00428-019-02696-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The first and family names of the authors were interchanged and are now presented correctly. The original article has been corrected.
Collapse
Affiliation(s)
- Arianna Di Napoli
- Pathology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University, Via di Grottarossa 1035, 00189, Rome, Italy.
| | - D Remotti
- Pathology Unit, San Camillo-Forlanini Hospital, Rome, Italy
| | - C Agostinelli
- Hematopathology Unit, S. Orsola University Hospital, Bologna, Italy
| | - M R Ambrosio
- Pathology Unit, Department of Medical Biotechnology, University of Siena, Siena, Italy
| | - S Ascani
- Pathology Unit, Ospedale di Terni, University of Perugia, Terni, Italy
| | - A Carbone
- Department of Pathology, Centro di Riferimento Oncologico di Aviano, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
| | - F Facchetti
- Pathology Section, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - S Lazzi
- Pathology Unit, Department of Medical Biotechnology, University of Siena, Siena, Italy
| | - L Leoncini
- Pathology Unit, Department of Medical Biotechnology, University of Siena, Siena, Italy
| | - M Lucioni
- Pathology Unit, University of Pavia and Fondazione IRCCS San Matteo Policlinico, Pavia, Italy
| | - D Novero
- Department of Oncology, University of Turin and Pathology Unit, AOU Città della Salute e della Scienza, Turin, Italy
| | - S Pileri
- Division of Haematopathology, European Institute of Oncology, Milan, Italy
| | - M Ponzoni
- Ateneo Vita-Salute, Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - E Sabattini
- Hematopathology Unit, S. Orsola University Hospital, Bologna, Italy
| | - C Tripodo
- Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy
- Tumor and Microenvironment Histopathology Unit, the FIRC Institute of Molecular Oncology (IFOM), Milan, Italy
| | - A Zamò
- Department of Oncology, University of Turin and Pathology Unit, AOU Città della Salute e della Scienza, Turin, Italy
| | - M Paulli
- Pathology Unit, University of Pavia and Fondazione IRCCS San Matteo Policlinico, Pavia, Italy
- Italian Group of Haematopathology (GIE), Rome, Italy
| | - L Ruco
- Pathology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University, Via di Grottarossa 1035, 00189, Rome, Italy
- Pathology Board of the Italian Lymphoma Foundation (FIL), Rome, Italy
| |
Collapse
|
4
|
Bruscaggin A, Mollejo M, Tapia G, Gomes da Silva M, Novak U, Dietrich S, Ponzoni M, Rambaldi A, Corradini P, Vitolo U, Merli M, Tzankov A, Cogliatti S, Montalban C, Marasca R, de Leval L, Visco C, Baptista M, Tousseyn T, Facchetti F, Paulli M, Mazzucchelli L, Bea S, Oscier D, Zinzani P, Bhagat G, Inghirami G, Gaidano G, Traverse-Glehen A, Thieblemont C, Piris M, Cavalli F, Arcaini L, Zucca E, Rossi D. MULTI-OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) - INTERIM ANALYSIS OF IELSG46 STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.138_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
5
|
Dodero A, Guidetti A, Tucci A, Barretta F, Novo M, Devizzi L, Re A, Passi A, Pellegrinelli A, Pruneri G, Miceli R, Testi A, Pennisi M, Di Chio MC, Matteucci P, Carniti C, Facchetti F, Rossi G, Corradini P. Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. Leukemia 2019; 33:1047-1051. [PMID: 30631117 PMCID: PMC6756077 DOI: 10.1038/s41375-018-0320-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2018] [Revised: 10/05/2018] [Accepted: 11/06/2018] [Indexed: 01/15/2023]
Affiliation(s)
- A Dodero
- Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - A Guidetti
- Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. .,Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.
| | - A Tucci
- Department of Hematology, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy
| | - F Barretta
- Department of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - M Novo
- Department of Hematology, Azienda Ospedaliero Universitaria Citta' della Salute e della Scienza di Torino, Torino, Italy
| | - L Devizzi
- Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - A Re
- Department of Hematology, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy
| | - A Passi
- Department of Hematology, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy
| | - A Pellegrinelli
- Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - G Pruneri
- Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.,Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - R Miceli
- Department of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - A Testi
- Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - M Pennisi
- Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - M C Di Chio
- Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - P Matteucci
- Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - C Carniti
- Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - F Facchetti
- Department of Pathology, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy
| | - G Rossi
- Department of Hematology, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy
| | - P Corradini
- Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.,Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy
| |
Collapse
|
6
|
Loglio A, Iavarone M, Grossi G, Viganò M, Rumi MG, Facchetti F, Lunghi G, Sangiovanni A, Colombo M, Lampertico P. Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B. Aliment Pharmacol Ther 2018; 48:431-439. [PMID: 29920698 DOI: 10.1111/apt.14848] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2018] [Revised: 03/02/2018] [Accepted: 05/23/2018] [Indexed: 12/11/2022]
Abstract
BACKGROUND Long-term oral nucleos(t)ide analogue (NUC) therapy in hepatitis B virus (HBV)-related compensated cirrhotics prevents clinical decompensation but not hepatocellular carcinoma (HCC) development. AIMS To define the clinical features and outcomes of HCC in long-term NUC-treated HBV patients. METHODS All HCCs developing between 2005 and 2016 in NUC-treated HBV patients under surveillance were studied, excluding those that occurred within the first 6 months of therapy. Clinical features of HCC, alpha faetoprotein (AFP) patterns and patients' outcome were studied. RESULTS Seventy-six HCC patients were included. Median age was 67 (40-83) years, 84% males, 96% Caucasian, 95% HBeAg-negative, 96% with undetectable HBV DNA, 83% with normal ALT levels, and 92% with compensated cirrhosis. Median serum AFP levels were 4 (1-3615) ng/mL (>7 ng/mL in 36%). HCC was monofocal in 78%, had a median diameter of 20 (6-57) mm and was in its early stage in 92% which allowed potentially curative treatments in 78% (39% ablation, 28% surgical resection, 11% liver transplantation). Overall, a complete response was obtained in 61 (80%) patients: in 40 after a first-line treatment, in 3 after the second-line treatment, in 2 after the third-line treatment, while 16 underwent liver transplantation (8 as second line). During 45 (7-144) months after HCC diagnosis, 19 patients died, 84% from HCC progression. The median time to recurrence was 20.2 (3-53) months, and the cumulative 5-year liver-related survival was 74%. CONCLUSIONS HCCs developing in patients under long-term NUC treatment were single, small tumours, amenable to curative therapies able to confer excellent 5-year survival rates.
Collapse
Affiliation(s)
- A Loglio
- CRC "A.M. e A. Migliavacca" Center for the Study of Liver Disease, Division of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy
| | - M Iavarone
- CRC "A.M. e A. Migliavacca" Center for the Study of Liver Disease, Division of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy
| | - G Grossi
- CRC "A.M. e A. Migliavacca" Center for the Study of Liver Disease, Division of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy
| | - M Viganò
- Hepatology Division, Ospedale San Giuseppe, Università degli Studi di Milano, Milan, Italy
| | - M G Rumi
- Hepatology Division, Ospedale San Giuseppe, Università degli Studi di Milano, Milan, Italy
| | - F Facchetti
- CRC "A.M. e A. Migliavacca" Center for the Study of Liver Disease, Division of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy
| | - G Lunghi
- Virology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy
| | - A Sangiovanni
- CRC "A.M. e A. Migliavacca" Center for the Study of Liver Disease, Division of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy
| | - M Colombo
- Center for Translational Hepatology Research, Clinical and Research Center, Humanitas Hospital, Rozzano, Italy
| | - P Lampertico
- CRC "A.M. e A. Migliavacca" Center for the Study of Liver Disease, Division of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy
| |
Collapse
|
7
|
Buffoli A, Olivetti L, Micheletti E, Facchetti F, Moretti R. Degree of Malignancy of Maxillary Sinus Cylindromas in Relation to Histologic Characteristics. Tumori 2018; 68:127-31. [PMID: 6289501 DOI: 10.1177/030089168206800205] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The authors, by analysing 31 cylindromas and 65 squamous cell carcinomas of the maxillary sinus, reached the conclusion that at a T2–T3, identical stage of development and with similar treatment, the carcinoma has a worse prognosis than the cylindroma, the latter being influenced in its clinical evolution by its histologic characteristics. In particular, the solid cellular pattern negatively affects the survival period.
Collapse
|
8
|
Schieppati F, Balzarini P, Fisogni S, Re A, Peli A, Passi A, Roccaro A, Lorenzi L, Cattaneo C, Facchetti F, Rossi G, Tucci A. Unfavorable prognostic impact of MYC
increased copy number (ICN) in patients with diffuse large B-cell (DLBCL) and high-grade lymphoma treated with immunochemotherapy. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- F. Schieppati
- Hematology; ASST Spedali Civili di Brescia; Brescia Italy
| | - P. Balzarini
- Pathology; ASST Spedali Civili di Brescia; Brescia Italy
| | - S. Fisogni
- Pathology; ASST Spedali Civili di Brescia; Brescia Italy
| | - A. Re
- Hematology; ASST Spedali Civili di Brescia; Brescia Italy
| | - A. Peli
- Hematology; ASST Spedali Civili di Brescia; Brescia Italy
| | - A. Passi
- Hematology; ASST Spedali Civili di Brescia; Brescia Italy
| | - A. Roccaro
- Hematology; ASST Spedali Civili di Brescia; Brescia Italy
| | - L. Lorenzi
- Pathology; ASST Spedali Civili di Brescia; Brescia Italy
| | - C. Cattaneo
- Hematology; ASST Spedali Civili di Brescia; Brescia Italy
| | - F. Facchetti
- Pathology; ASST Spedali Civili di Brescia; Brescia Italy
| | - G. Rossi
- Hematology; ASST Spedali Civili di Brescia; Brescia Italy
| | - A. Tucci
- Hematology; ASST Spedali Civili di Brescia; Brescia Italy
| |
Collapse
|
9
|
Apalla Z, Calzavara-Pinton P, Lallas A, Argenziano G, Kyrgidis A, Crotti S, Facchetti F, Monari P, Gualdi G. Histopathological study of perilesional skin in patients diagnosed with nonmelanoma skin cancer. Clin Exp Dermatol 2015; 41:21-5. [PMID: 26189480 DOI: 10.1111/ced.12713] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/10/2015] [Indexed: 11/30/2022]
Abstract
BACKGROUND Epidemiological and clinical data suggest that actinic damage to the skin is an important predictor of skin carcinogenesis. AIM To investigate the association of squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) with sun-damage alterations seen by histopathology. METHOD In the current prospective study, perilesional skin of SCC or BCC lesions was evaluated for presence of alterations associated with chronic photodamage. Presence of scarring, perineural/perivascular invasion, haemorrhage/haemorrhagic crust, ulceration/erosion and margin involvement were also assessed. RESULT Of 6038 included lesions, 4523 (74.9%) were BCCs and 1515 (25.1%) were SCCs. Presence of actinic damage was five times more frequent in SCC than in BCC (OR = 5.29, 95% CI 4.44-6.00, P < 0.001), and diagnosis of SCC was twice as common in photo-exposed than nonphoto-exposed body sites (OR = 2.34, 95% CI 2.03-2.70, P < 0.001). There were twofold higher odds for actinic damage in SCC compared with Bowen disease (OR = 2.015, 95% CI 1.55-2.61, P < 0.001). Assessing the different BCC histological subtypes, we found that nodular BCC had at least twofold higher odds (OR = 2.63, 95% CI 2.09-3.32), infiltrative BCC had 48% higher odds (OR = 1.487, 95% CI 1.18-1.87) and basosquamous BCC had fourfold higher odds (OR = 4.10, 95% CI 3.01-5.57) of having actinic damage compared with superficial BCC. CONCLUSIONS Histological verification of ultraviolet-associated alterations in the perilesional skin in patients with NMSC in our study confirms the aetiopathogenic link between sun exposure and epithelial carcinogenesis on a histopathological basis. This correlation was stronger for SCCs than for BCCs.
Collapse
Affiliation(s)
- Z Apalla
- First Department of Dermatology, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | | | - A Lallas
- Skin Cancer Unit, Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia, Italy
| | - G Argenziano
- Skin Cancer Unit, Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia, Italy
| | - A Kyrgidis
- Skin Cancer Unit, Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia, Italy
| | - S Crotti
- Department of Dermatology, Spedali Civili Brescia, Brescia, Italy
| | - F Facchetti
- Department of Pathology 1-2, Spedali Civili Brescia, Brescia, Italy
| | - P Monari
- Department of Dermatology, Spedali Civili Brescia, Brescia, Italy
| | - G Gualdi
- Department of Dermatology, Spedali Civili Brescia, Brescia, Italy
| |
Collapse
|
10
|
Sandrini S, Scolari F, Savoldi S, Brunori G, Callea F, Tardanico R, Facchetti F, Delaini C, Cristinelli L, Maiorca R. Liver disease in renal transplant patients treated with azathioprine or ciclosporin. Contrib Nephrol 2015; 51:114-9. [PMID: 3032510 DOI: 10.1159/000413106] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
11
|
Haspeslagh M, Noë M, De Wispelaere I, Degryse N, Vossaert K, Lanssens S, Facchetti F, Van Den Bossche K, Brochez L. Rosettes and other white shiny structures in polarized dermoscopy: histological correlate and optical explanation. J Eur Acad Dermatol Venereol 2015; 30:311-3. [PMID: 25786770 DOI: 10.1111/jdv.13080] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2014] [Accepted: 02/09/2015] [Indexed: 11/28/2022]
Abstract
BACKGROUND Rosettes are a specific form of a white shiny structure seen with polarized dermoscopy. The precise morphological correlate and optical explication are not known. OBJECTIVE To estimate the frequency of rosettes in ex vivo dermoscopy and to find explication and morphologic correlate of this dermoscopic feature. METHODS A series of 6108 consecutive skin biopsies were examined with ex vivo dermoscopy and when rosettes were present serial transverse sections with polarization were examined. RESULTS In this series of 6108 consecutive skin biopsies, rosettes were found on ex vivo dermoscopy in 63 cases. When multiple we observed that they are always oriented at the same angle. Transverse sections with polarization of these lesions proved that smaller rosettes are mainly caused by polarizing horny material in adnexal openings, and larger rosettes by concentric perifollicular fibrosis. CONCLUSIONS Rosettes are an optical effect of crossed polarization by concentric fibrosis or horny material and hence are not lesion-specific.
Collapse
Affiliation(s)
| | - M Noë
- Dermpat, Ardooie, Belgium
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Gualdi G, Lorenzi L, Arisi M, Maffeis M, Soresina A, Marocolo D, Plebani A, Calzavara-Pinton PG, Facchetti F. Acral lympho-histiocytic dermatitis in X-linked agammaglobulinemia: a case report showing clonal CD8(+) T cells with indolent clinical behaviour. J Eur Acad Dermatol Venereol 2014; 30:461-3. [PMID: 25388899 DOI: 10.1111/jdv.12839] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- G Gualdi
- Dermatology Unit, Spedali Civili di Brescia, University of Brescia, Brescia, Italy
| | - L Lorenzi
- Pathology Section, Department of Molecular and Translational Medicine, Spedali Civili di Brescia, University of Brescia, Brescia, Italy
| | - M Arisi
- Dermatology Unit, Spedali Civili di Brescia, University of Brescia, Brescia, Italy
| | - M Maffeis
- Pediatrics Clinic, Spedali Civili di Brescia, University of Brescia, Brescia, Italy
| | - A Soresina
- Pediatrics Clinic, Spedali Civili di Brescia, University of Brescia, Brescia, Italy
| | - D Marocolo
- Pathology Section, Department of Molecular and Translational Medicine, Spedali Civili di Brescia, University of Brescia, Brescia, Italy
| | - A Plebani
- Pediatrics Clinic, Spedali Civili di Brescia, University of Brescia, Brescia, Italy
| | - P G Calzavara-Pinton
- Dermatology Unit, Spedali Civili di Brescia, University of Brescia, Brescia, Italy
| | - F Facchetti
- Pathology Section, Department of Molecular and Translational Medicine, Spedali Civili di Brescia, University of Brescia, Brescia, Italy
| |
Collapse
|
13
|
Galmozzi E, Facchetti F, Perbellini R, Aghemo A. High-resolution melting assay for genotyping of IFNL4-associated dinucleotide variant rs368234815. Clin Microbiol Infect 2014; 20:O936-8. [DOI: 10.1111/1469-0691.12637] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2013] [Revised: 02/18/2014] [Accepted: 03/26/2014] [Indexed: 01/21/2023]
|
14
|
Gualdi G, Monari P, Crotti S, Damiani G, Facchetti F, Calzavara‐Pinton P, Fantini F. Matter of margins. J Eur Acad Dermatol Venereol 2014; 29:255-261. [DOI: 10.1111/jdv.12504] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2013] [Accepted: 03/05/2014] [Indexed: 11/30/2022]
Affiliation(s)
- G. Gualdi
- Department of Dermatology Spedali Civili‐University of Brescia Brescia Italy
| | - P. Monari
- Department of Dermatology Spedali Civili‐University of Brescia Brescia Italy
| | - S. Crotti
- Department of Dermatology Spedali Civili‐University of Brescia Brescia Italy
| | - G. Damiani
- Department of Dermatology Spedali Civili‐University of Brescia Brescia Italy
| | - F. Facchetti
- Department of Pathology I and II Spedali Civili‐University of Brescia Brescia Italy
| | - P. Calzavara‐Pinton
- Department of Dermatology Spedali Civili‐University of Brescia Brescia Italy
| | - F. Fantini
- Department of Dermatology Ospedale ‘A.Manzoni’ Lecco Italy
| |
Collapse
|
15
|
Trembling PM, Lampertico P, Parkes J, Tanwar S, Viganò M, Facchetti F, Colombo M, Rosenberg WM. Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. J Viral Hepat 2014; 21:430-8. [PMID: 24750297 PMCID: PMC4298014 DOI: 10.1111/jvh.12161] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Assessment of liver fibrosis is important in determining prognosis, disease progression and need for treatment in patients with chronic hepatitis B (CHB). Limitations to the use of liver biopsy in assessing fibrosis are well recognized, and noninvasive tests are being increasingly evaluated including transient elastography (TE) and serum markers such as the Enhanced Liver Fibrosis (ELF) test. We assessed performance of ELF and TE in detecting liver fibrosis with reference to liver histology in a cohort of patients with CHB (n = 182), and compared the performance of these modalities. Median age was 46 and mean AST 70 IU/L. Cirrhosis was reported in 20% of liver biopsies. Both modalities performed well in assessing fibrosis at all stages. Area under receiver operator characteristic (AUROC) curves for detecting METAVIR fibrosis stages F ≥ 1, F ≥ 2, F ≥ 3 and F4 were 0.77, 0.82, 0.80 and 0.83 for ELF and 0.86, 0.86, 0.90 and 0.95 for TE. TE performed significantly better in the assessment of severe fibrosis (AUROC 0.80 for ELF and 0.90 for TE, P < 0.01) and cirrhosis (0.83 for ELF and 0.95 for TE, P < 0.01). This study demonstrates that ELF has good performance in detection of liver fibrosis in patients with CHB, and when compared, TE performs better in detection of severe fibrosis/cirrhosis.
Collapse
Affiliation(s)
- P M Trembling
- Institute for Liver and Digestive Health, Division of Medicine, University College LondonLondon, UK
| | - P Lampertico
- AM and A Migliavacca Center for Liver Disease, 1st Division of Gastroenterology, Department of Medicine, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di MilanoMilan, Italy
| | - J Parkes
- Public Health Sciences and Medical Statistics, Faculty of Medicine, University of SouthamptonSouthampton, UK
| | - S Tanwar
- Institute for Liver and Digestive Health, Division of Medicine, University College LondonLondon, UK
| | - M Viganò
- AM and A Migliavacca Center for Liver Disease, 1st Division of Gastroenterology, Department of Medicine, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di MilanoMilan, Italy,UO Epatologia, Ospedale San Giuseppe, Università degli Studi di MilanoMilan, Italy
| | - F Facchetti
- AM and A Migliavacca Center for Liver Disease, 1st Division of Gastroenterology, Department of Medicine, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di MilanoMilan, Italy
| | - M Colombo
- AM and A Migliavacca Center for Liver Disease, 1st Division of Gastroenterology, Department of Medicine, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di MilanoMilan, Italy
| | - W M Rosenberg
- Institute for Liver and Digestive Health, Division of Medicine, University College LondonLondon, UK
| |
Collapse
|
16
|
Hartmann S, Döring C, Jakobus C, Rengstl B, Newrzela S, Tousseyn T, Sagaert X, Ponzoni M, Facchetti F, de Wolf-Peeters C, Steidl C, Gascoyne R, Küppers R, Hansmann ML. Nodular Lymphocyte Predominant Hodgkin Lymphoma and T cell/Histiocyte Rich Large B Cell Lymphoma Endpoints of a Spectrum of one Disease? Klin Padiatr 2014. [DOI: 10.1055/s-0034-1371130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
17
|
Sapienza MR, Fuligni F, Agostinelli C, Tripodo C, Righi S, Laginestra MA, Pileri A, Mancini M, Rossi M, Ricci F, Gazzola A, Melle F, Mannu C, Ulbar F, Arpinati M, Paulli M, Maeda T, Gibellini D, Pagano L, Pimpinelli N, Santucci M, Cerroni L, Croce CM, Facchetti F, Piccaluga PP, Pileri SA. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia 2014; 28:1606-16. [PMID: 24504027 PMCID: PMC4294271 DOI: 10.1038/leu.2014.64] [Citation(s) in RCA: 121] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2013] [Revised: 01/07/2014] [Accepted: 01/28/2014] [Indexed: 12/12/2022]
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease of controversial origin recently recognized as a neoplasm deriving from plasmacytoid dendritic cells (pDCs). Nevertheless, it remains an orphan tumor with obscure biology and dismal prognosis. To better understand the pathobiology of BPDCN and discover new targets for effective therapies, the gene expression profile (GEP) of 25 BPDCN samples was analyzed and compared with that of pDCs, their postulated normal counterpart. Validation was performed by immunohistochemistry (IHC), whereas functional experiments were carried out ex vivo. For the first time at the molecular level, we definitely recognized the cellular derivation of BPDCN that proved to originate from the myeloid lineage and in particular, from resting pDCs. Furthermore, thanks to an integrated bioinformatic approach we discovered aberrant activation of the NF-kB pathway and suggested it as a novel therapeutic target. We tested the efficacy of anti-NF-kB-treatment on the BPDCN cell line CAL-1, and successfully demonstrated by GEP and IHC the molecular shutoff of the NF-kB pathway. In conclusion, we identified a molecular signature representative of the transcriptional abnormalities of BPDCN and developed a cellular model proposing a novel therapeutic approach in the setting of this otherwise incurable disease.
Collapse
Affiliation(s)
- M R Sapienza
- Department of Experimental, Diagnostic, and Specialty Medicine, Hematopathology & Hematology Sections, Molecular Pathology Laboratory, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy
| | - F Fuligni
- Department of Experimental, Diagnostic, and Specialty Medicine, Hematopathology & Hematology Sections, Molecular Pathology Laboratory, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy
| | - C Agostinelli
- Department of Experimental, Diagnostic, and Specialty Medicine, Hematopathology & Hematology Sections, Molecular Pathology Laboratory, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy
| | - C Tripodo
- Department of Health Science, Tumour Immunology Unit, Human Pathology Section University of Palermo School of Medicine, Palermo, Italy
| | - S Righi
- Department of Experimental, Diagnostic, and Specialty Medicine, Hematopathology & Hematology Sections, Molecular Pathology Laboratory, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy
| | - M A Laginestra
- Department of Experimental, Diagnostic, and Specialty Medicine, Hematopathology & Hematology Sections, Molecular Pathology Laboratory, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy
| | - A Pileri
- Department of Surgery and Translational Medicine - Division Dermatology, University of Florence, Florence, Italy
| | - M Mancini
- Department of Experimental, Diagnostic, and Specialty Medicine, Hematopathology & Hematology Sections, Molecular Pathology Laboratory, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy
| | - M Rossi
- Department of Experimental, Diagnostic, and Specialty Medicine, Hematopathology & Hematology Sections, Molecular Pathology Laboratory, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy
| | - F Ricci
- Department of Hematology, Oncology and Laboratory Medicine, Transfusion Medicine Service, S. Orsola-Malpighi Hospital, Bologna, Italy
| | - A Gazzola
- Department of Experimental, Diagnostic, and Specialty Medicine, Hematopathology & Hematology Sections, Molecular Pathology Laboratory, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy
| | - F Melle
- Department of Experimental, Diagnostic, and Specialty Medicine, Hematopathology & Hematology Sections, Molecular Pathology Laboratory, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy
| | - C Mannu
- Department of Experimental, Diagnostic, and Specialty Medicine, Hematopathology & Hematology Sections, Molecular Pathology Laboratory, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy
| | - F Ulbar
- Department of Experimental, Diagnostic, and Specialty Medicine, Hematopathology & Hematology Sections, Molecular Pathology Laboratory, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy
| | - M Arpinati
- Department of Experimental, Diagnostic, and Specialty Medicine, Hematopathology & Hematology Sections, Molecular Pathology Laboratory, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy
| | - M Paulli
- Anatomic Pathology Section, University of Pavia Medical School, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione Policlinico, San Matteo, Pavia, Italy
| | - T Maeda
- Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - D Gibellini
- Department of Experimental, Diagnostic, and Specialty Medicine, Microbiology Section, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy
| | - L Pagano
- Institute of Hematology, Catholic University, Rome, Italy
| | - N Pimpinelli
- Department of Surgery and Translational Medicine - Division Dermatology, University of Florence, Florence, Italy
| | - M Santucci
- Department of Surgery and Translational Medicine, Pathologic Anatomy Division, University of Florence, Florence, Italy
| | - L Cerroni
- Department of Dermatology, Medical University of Graz, Graz, Austria
| | - C M Croce
- Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - F Facchetti
- Department of Molecular and Translational Medicine, Pathology Section, University of Brescia, Brescia, Italy
| | - P P Piccaluga
- Department of Experimental, Diagnostic, and Specialty Medicine, Hematopathology & Hematology Sections, Molecular Pathology Laboratory, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy
| | - S A Pileri
- Department of Experimental, Diagnostic, and Specialty Medicine, Hematopathology & Hematology Sections, Molecular Pathology Laboratory, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy
| | | |
Collapse
|
18
|
Abstract
We describe herein a case of IgG4-related disease with the isolated clinical presentation of malabsorption due to pancreatic failure. Histology of an abdominal lymph node was critical for diagnosis. IgG4-related disease is increasingly recognized as an immunological disorder that can mimic various clinical entities.
Collapse
Affiliation(s)
- C. Lombardi
- Allergy and Immunology Unit, Department of Internal Medicine, Sant'Orsola-Poliambulanza Hospital, Brescia, Italy
| | - D. Belli
- Allergy and Immunology Unit, Department of Internal Medicine, Sant'Orsola-Poliambulanza Hospital, Brescia, Italy
| | - F. Facchetti
- Department of Pathology I; Spedali Civili-University of Brescia, Italy
| | - G. Passalacqua
- Allergy and Respiratory Diseases, DIMI, University of Genoa, Genoa (Italy)
| |
Collapse
|
19
|
Fazzi E, Cattalini M, Orcesi S, Tincani A, Andreoli L, Balottin U, De Simone M, Fredi M, Facchetti F, Galli J, Giliani S, Izzotti A, Meini A, Olivieri I, Plebani A. Aicardi–Goutieres syndrome, a rare neurological disease in children: A new autoimmune disorder? Autoimmun Rev 2013; 12:506-9. [DOI: 10.1016/j.autrev.2012.08.012] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2012] [Accepted: 08/13/2012] [Indexed: 01/08/2023]
|
20
|
Galmozzi E, Facchetti F, Degasperi E, Aghemo A, Lampertico P. Allelic inhibition of displacement activity: a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms. J Virol Methods 2012. [PMID: 23201294 DOI: 10.1016/j.jviromet.2012.11.026] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Recently, genome-wide association studies (GWAS) in patients with chronic hepatitis C virus (HCV) infection have identified two functional single nucleotide polymorphisms (SNPs) in the inosine triphosphatase (ITPA) gene, that are associated strongly and independently with hemolytic anemia in patients exposed to pegylated-interferon (Peg-IFN) plus ribavirin (RBV) combined therapy. Here has been developed a simplified allele discrimination polymerase chain reaction (PCR) assay named allelic inhibition of displacement activity (AIDA) for evaluation of ITPA polymorphisms. AIDA system relies on three unlabeled primers only, two outer common primers and one inner primer with allele-specific 3' terminus mismatch. DNA samples from 192 patients with chronic HCV infection were used to validate the AIDA system and results were compared with the gold standard TaqMan(®) SNP genotyping assay. Concordant data were obtained for all samples, granting for high specificity of the method. In conclusion, AIDA is a practical one-tube method to reproducibly and to assess accurately rs7270101 and rs1127354 ITPA SNPs.
Collapse
Affiliation(s)
- E Galmozzi
- First Division of Gastroenterology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.
| | | | | | | | | |
Collapse
|
21
|
Ferreri A, Ponzoni M, Govi S, Pasini E, Mappa S, Vino A, Facchetti F, Vezzoli P, Doglioni C, Berti E, Dolcetti R. Prevalence of chlamydial infection in a series of 108 primary cutaneous lymphomas. Br J Dermatol 2012; 166:1121-3. [DOI: 10.1111/j.1365-2133.2011.10704.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
| | - M. Ponzoni
- Unit of Lymphoid Malignancies
- Pathology Unit
| | - S. Govi
- Unit of Lymphoid Malignancies
| | - E. Pasini
- Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, IRCCS National Cancer Institute, Aviano, Italy
| | - S. Mappa
- Unit of Lymphoid Malignancies
- Unit of Internal Medicine, Department of Onco‐Hematology, San Raffaele Scientific Institute, Milan, Italy
| | | | - F. Facchetti
- Pathology Unit, Spedali Civili di Brescia, Brescia, Italy
| | - P. Vezzoli
- Division of Dermatology, IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milano‐Bicocca, Milan, Italy
E‐mail:
A.J.M.F. and M.P. contributed equally to this work. E.B. and R.D. shared senior authorship
| | | | - E. Berti
- Division of Dermatology, IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milano‐Bicocca, Milan, Italy
E‐mail:
A.J.M.F. and M.P. contributed equally to this work. E.B. and R.D. shared senior authorship
| | - R. Dolcetti
- Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, IRCCS National Cancer Institute, Aviano, Italy
| |
Collapse
|
22
|
Rizvi H, Paterson JC, Tedoldi S, Ramsay A, Calaminici M, Natkunam Y, Lonardi S, Tan SY, Campbell L, Hansmann ML, Jones D, Dikic I, Shaw AS, Pileri SA, Stein H, Mason DY, Facchetti F, Marafioti T. Expression of the CD2AP adaptor molecule in normal, reactive and neoplastic human tissue. Pathologica 2012; 104:56-64. [PMID: 22953501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023] Open
Abstract
AIMS To study the expression of CD2-associated protein (CD2AP), an adaptor protein involved in T-cell signalling and renal function, in normal, reactive and neoplastic human lymphoid tissues. METHODS AND RESULTS We used immunohistochemical techniques to evaluate monoclonal antibodies against CD2AP on over 400 formalin fixed paraffin embedded tissue blocks retrieved from the host institutions of three authors. The samples tested included normal, reactive and neoplastic lymphoid tissue. In lymphoid tissues, strong CD2AP staining was observed in plasmacytoid dendritic cells (pDCs), weak and variable in mantle zone B cells and moderate in rare germinal center cells. CD2AP labeled cortical and rare medullary thymocytes and isolated mononuclear cells in bone marrow trephines. Furthermore, epithelial and endothelial cells expressed CD2AP. Among neoplasms, the greatest number of CD2AP-positive cases were found in diffuse large B cell (21/94), NK T-cell lymphomas (7/67), "blastic plasmacytoid dendritic cell neoplasms" (9/10) and some types of solid tumor. CONCLUSIONS Our finding that mature peripheral T cells are CD2AP-negative but immature cortical thymocytes are positive may prove useful for diagnostic purposes. Moreover, our results demonstrate that CD2AP represents a useful marker of normal and neoplastic pDC and may be used in a diagnostic panel in reactive or neoplastic lymphoid proliferations.
Collapse
Affiliation(s)
- H Rizvi
- Department of Cellular Pathology, Barts and The London NHS Trust, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Mian M, Scandurra M, Chigrinova E, Shen Y, Inghirami G, Greiner TC, Chan WC, Vose JM, Testoni M, Chiappella A, Baldini L, Ponzoni M, Ferreri AJM, Franceschetti S, Gaidano G, Montes-Moreno S, Piris MA, Facchetti F, Tucci A, Nomdedeu JF, Lazure T, Uccella S, Tibiletti MG, Zucca E, Kwee I, Bertoni F. Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. Ann Oncol 2012; 23:729-735. [PMID: 21693768 DOI: 10.1093/annonc/mdr289] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Deletions at 13q14.3 are common in chronic lymphocytic leukemia and are also present in diffuse large B-cell lymphomas (DLBCL) but never in immunodeficiency-related DLBCL. To characterize DLBCL with 13q14.3 deletions, we combined genome-wide DNA profiling, gene expression and clinical data in a large DLBCL series treated with rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone repeated every 21 days (R-CHOP21). PATIENTS AND METHODS Affymetrix GeneChip Human Mapping 250K NspI and U133 plus 2.0 gene were used. MicroRNA (miRNA) expression was studied were by real-time PCR. Median follow-up of patients was 4.9 years. RESULTS Deletions at 13q14.3, comprising DLEU2/MIR15A/MIR16, occurred in 22/166 (13%) cases. The deletion was wider, including also RB1, in 19/22 cases. Samples with del(13q14.3) had concomitant specific aberrations. No reduced MIR15A/MIR16 expression was observed, but 172 transcripts were significantly differential expressed. Among the deregulated genes, there were RB1 and FAS, both commonly deleted at genomic level. No differences in outcome were observed in patients treated with R-CHOP21. CONCLUSIONS Cases with 13q14.3 deletions appear as group of DLBCL characterized by common genetic and biologic features. Deletions at 13q14.3 might contribute to DLBCL pathogenesis by two mechanisms: deregulating the cell cycle control mainly due RB1 loss and contributing to immune escape, due to FAS down-regulation.
Collapse
Affiliation(s)
- M Mian
- Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Division of Hematology, Azienda Ospedaliera S. Maurizio, Bolzano/Bozen, Italy
| | - M Scandurra
- Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - E Chigrinova
- Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Y Shen
- Department of Pathology and Microbiology, University of Nebraska, Omaha, USA
| | - G Inghirami
- Department of Pathology and Center for Experimental Research and Medical Studies, University of Turin, Turin
| | - T C Greiner
- Department of Pathology and Microbiology, University of Nebraska, Omaha, USA
| | - W C Chan
- Department of Pathology and Microbiology, University of Nebraska, Omaha, USA
| | - J M Vose
- Department of Pathology and Microbiology, University of Nebraska, Omaha, USA
| | - M Testoni
- Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - A Chiappella
- Department of Pathology and Center for Experimental Research and Medical Studies, University of Turin, Turin
| | - L Baldini
- Hematology/Bone Marrow Transplantation Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, University of Milan, Milan
| | - M Ponzoni
- Pathology Unit and Unit of Lymphoid Malignancies, San Raffaele Scientific Institute, Milan
| | - A J M Ferreri
- Pathology Unit and Unit of Lymphoid Malignancies, San Raffaele Scientific Institute, Milan
| | - S Franceschetti
- Division of Hematology, Department of Clinical and Experimental Medicine & Centro di Biotecnologie per la Ricerca Medica Applicata, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
| | - G Gaidano
- Division of Hematology, Department of Clinical and Experimental Medicine & Centro di Biotecnologie per la Ricerca Medica Applicata, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
| | - S Montes-Moreno
- Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - M A Piris
- Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - F Facchetti
- Department of Pathology, University of Brescia, I Servizio di Anatomia Patologica, Spedali Civili di Brescia, Brescia; Division of Hematology, Spedali Civili di Brescia, Brescia, Italy
| | - A Tucci
- Department of Pathology, University of Brescia, I Servizio di Anatomia Patologica, Spedali Civili di Brescia, Brescia; Division of Hematology, Spedali Civili di Brescia, Brescia, Italy
| | - J Fr Nomdedeu
- Department of Hematology and Laboratori d'Hematologia, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - T Lazure
- Departments of Internal Medicine and Pathology, University Hospital of Bicêtre, AP/HP, Le Kremlin Bicêtre, France
| | - S Uccella
- Anatomic Pathology Unit, University of Insubria, Ospedale di Circolo, Varese, Italy
| | - M G Tibiletti
- Anatomic Pathology Unit, University of Insubria, Ospedale di Circolo, Varese, Italy
| | - E Zucca
- Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - I Kwee
- Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dalle Molle Institute for Artificial Intelligence (IDSIA), Manno, Switzerland
| | - F Bertoni
- Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
| |
Collapse
|
24
|
Salemme M, Rodella R, Fisogni S, Facchetti F. Nodular extramedullary hematopoiesis involving the adrenal gland. An uncommon cause of adrenal "incidentaloma". Pathologica 2011; 103:46-49. [PMID: 21797143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023] Open
Abstract
Adrenal extramedullary hematopoiesis may occur in association with various hematologic diseases. Its identification is invariably incidental, imaging of the lesion is poorly specific and the diagnosis requires the histological examination. We report a case of extramedullary hematopoiesis involving the right adrenal gland in a patient with hereditary spherocytosis. The literature on this entity has been reviewed and the differential with other conditions involving the adrenal gland and showing hematopoietic tissue infiltration is discussed.
Collapse
Affiliation(s)
- M Salemme
- Department of Pathology I, Spedali Civili, University of Brescia, Italy.
| | | | | | | |
Collapse
|
25
|
Manganoni AM, Facchetti F, Gavazzoni F, Farisoglio C, Manca G, Sereni E, Marocolo D, Calzavara-Pinton PG. Letter: Acral-lentiginous melanoma: Report of 15 cases. Dermatol Online J 2011; 17:15. [PMID: 21272506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023] Open
|
26
|
Manganoni AM, Facchetti F, Gavazzoni F, Farisoglio C, Manca G, Sereni E, Marocolo D, Calzavara-Pinton PG. Acral-lentiginous melanoma: Report of 15 cases. Dermatol Online J 2011. [DOI: 10.5070/d35cw9x5kt] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
|
27
|
Viganò M, Vener C, Lampertico P, Annaloro C, Pichoud C, Zoulim F, Facchetti F, Poli F, Scalamogna M, Deliliers GL, Colombo M. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant 2010; 46:125-31. [PMID: 20383209 DOI: 10.1038/bmt.2010.70] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Allogeneic hematopoietic SCT (HSCT) increases the risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg) carriers but the incidence, risk factors and course of HBV reactivation after HSCT in HBsAg-negative/anti-hepatitis B core antigen (anti-HBc)-positive recipients are not well known. A total of 50 HBsAg-negative/anti-HBc-positive HSCT recipients with onco-hematological diseases, underwent sequential clinical and laboratory examinations, including serum HBsAg, during follow-up. Serum HBV DNA collected at HSCT was retrospectively amplified by a sensitive PCR assay. During 17 months of follow-up, six (12%) patients had seroreverted to HBsAg, 7-32 months after HSCT, with 1- and 5-year cumulative rates of 13 and 22%. HBsAg seroreversion was associated with serum HBeAg higher than 8 log₁₀ copies per ml HBV DNA and a 1.5 to 36 fold increase of serum alanine aminotransferase leading to HBeAg-positive chronic hepatitis B in all patients. Patients with chronic onco-hematological disease and long-lasting immunosuppression following HSCT had a higher risk of HBsAg seroreversion independently of serum HBV DNA levels at HSCT. HBsAg-negative/anti-HBc-positive HSCT recipients with chronic onco-hematological disease carry a significant risk of HBsAg seroreversion and HBeAg-positive chronic hepatitis B, independently of serum levels of HBV DNA at transplantation.
Collapse
Affiliation(s)
- M Viganò
- First Division of Gastroenterology, Department of Medicine, A M and A Migliavacca Center for Liver Disease, Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico, Università di Milano, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Pagano L, Valentini CG, Posteraro B, Girmenia C, Ossi C, Pan A, Candoni A, Nosari A, Riva M, Cattaneo C, Rossini F, Fianchi L, Caira M, Sanguinetti M, Gesu GP, Lombardi G, Vianelli N, Stanzani M, Mirone E, Pinsi G, Facchetti F, Manca N, Savi L, Mettimano M, Selva V, Caserta I, Scarpellini P, Morace G, D'Arminio Monforte A, Grossi P, Giudici D, Tortorano AM, Bonini A, Ricci L, Picardi M, Rossano F, Fanci R, Pecile P, Fumagalli L, Ferrari L, Capecchi PL, Romano C, Busca A, Barbui A, Garzia M, Minniti RR, Farina G, Montagna MT, Bruno F, Morelli O, Chierichini A, Placanica PM, Castagnola E, Bandettini R, Giordano S, Monastero R, Tosti ME, Rossi MR, Spedini P, Piane R, Nucci M, Pallavicini F, Bassetti M, Cristini F, LA Sorda M, Viviani M. Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology). J Chemother 2009; 21:322-9. [PMID: 19567354 DOI: 10.1179/joc.2009.21.3.322] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
The aims of the study were to analyze the clinical and epidemiological characteristics and treatments for patients who developed zygomycosis enrolled in Italy during the European Confederation of Medical Mycology of medical mycology survey. This prospective multicenter study was performed between 2004 and 2007 at 49 italian Departments. 60 cases of zygomycosis were enrolled: the median age was 59.5 years (range 1-87), with a prevalence of males (70%). The majority of cases were immunocompromised patients (42 cases, 70%), mainly hematological malignancies (37). Among non-immunocompromised (18 cases, 30%), the main category was represented by patients with penetrating trauma (7/18, 39%). The most common sites of infection were sinus (35%) with/without CNS involvement, lung alone (25%), skin (20%), but in 11 cases (18%) dissemination was observed. According to EORTC criteria, the diagnosis of zygomycosis was proven in 46 patients (77%) and in most of them it was made in vivo (40/46 patients, 87%); in the remaining 14 cases (23%) the diagnosis was probable. 51 patients received antifungal therapy and in 30 of them surgical debridement was also performed. The most commonly used antifungal drug was liposomal amphotericin B (L-AmB), administered in 44 patients: 36 of these patients (82%) responded to therapy. Altogether an attributable mortality rate of 32% (19/60) was registered, which was reduced to 18% in patients treated with L-AmB (8/44). Zygomycosis is a rare and aggressive filamentous fungal infection, still associated with a high mortality rate. This study indicates an inversion of this trend, with a better prognosis and significantly lower mortality than that reported in the literature. It is possible that new extensive, aggressive diagnostic and therapeutic procedures, such as the use of L-AmB and surgery, have improved the prognosis of these patients.
Collapse
Affiliation(s)
- L Pagano
- Instituto di Ematologia, Università Cattolica del Sacro Cuore, Roma.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Cattaneo C, Facchetti F, Re A, Borlenghi E, Majorana A, Bardellini E, Casari S, Tucci A, Conti G, Rossi G. Oral cavity lymphomas in immunocompetent and human immunodeficiency virus infected patients. Leuk Lymphoma 2009; 46:77-81. [PMID: 15621784 DOI: 10.1080/10428190400007789] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Oral cavity lymphoma (OCL) seems to occur more frequently in HIV-positive patients, but it is presently unknown whether HIV-related immune deficit plays a role in modifying the prevalence and the characteristics of these lymphomas. To clarify this issue, we compared OCL occurring in immunocompetent and HIV-positive patients. A comparison was made between cases of OCL occurring among 543 and 123 NHL consecutively diagnosed at a single center in immunocompetent and HIV-positive patients respectively. The prevalence of oral cavity involvement at diagnosis was significantly lower in the immunocompetent subgroup (HIV-negative: 1.66%; HIV-positive: 7.3%, P = 0.002). Extranodal T/NK nasal-nasal-type lymphoma (ET/NK-NL) was observed in 3 of 9 immunocompetent patients, whereas plasmablastic lymphoma (PBL) was observed in 3 of 9 HIV-positive patients. EBV expression correlated with HIV-positivity. Response to treatment was similar between the two subgroups, but the overall prognosis was significantly worse among HIV-positive patients. Median survival was 34 months in immunocompetent vs. 9 months in HIV-positive patients (P < 0.01). A higher frequency of oral cavity lymphoma was associated with HIV infection. ET/NK-NL and PBL seemed to be clinical entities characteristically related to immunocompetent and HIV-positive subgroups, respectively. Chemotherapy was feasible and effective in both subgroups, although a poor prognosis was associated with immunodeficiency.
Collapse
Affiliation(s)
- C Cattaneo
- U.O. Ematologia, Spedali Civili, Brescia, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Grisanti S, Consoli F, Ferrari VD, Bercich L, Amoroso V, Rangoni G, Cetto GL, Dei Tos AP, Facchetti F, Marini G. Proliferation heterogeneity in synovial sarcoma (SS) defines different patterns of clinical outcome: A retrospective study of 32 patients. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e21511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e21511 Background: SS is an aggressive soft tissue sarcoma (STS) characterized by a constitutive overexpression of the bcl-2 proteins and high proliferation rate (Ki67). The aim of the study was to evaluate prognostic value of proliferative activity and apoptosis in SS. Methods: A retrospective analysis of 32 patients treated at three oncology centers between January 2000 and August 2008 was conducted. Histologic diagnosis of SS was confirmed by FISH analysis of t(X;18). Bcl-2 and Ki67 were determined by immunohistochemistry at baseline and after neoadjuvant chemotherapy (CT). A cut-off value of 20% was established for Ki67. The bcl-2 gene status was evaluated by FISH in neoadjuvant subgroup. Treatment-induced pathological response (pCR) was defined as tumor necrosis of 100%. Endpoints were recurrence rate (RR), disease-free survival (DFS) and overall survival (OS). Clinical and pathological variables were considered in uni- and multivariate analysis. Results: 13/32 patients received an anthracycline/ifosfamide-based chemotherapy (CT) before surgery. 8 pts received concomitant radiotherapy. A median number of 3 cycles of neoadjuvant CT was administered. All patients underwent surgical resection and pathologic assessment of the coexpression of bcl-2 and Ki67 was evaluated in the resected specimens. At baseline, all samples showed immunoexpression of bcl-2 and 9/13 had Ki67 more than 20%. After neoadjuvant CT, Ki67 was downregulated <20% in 11/13 samples and bcl-2 was negative in 4/13 pts. At FISH analysis, bcl-2 gene was neither rearranged nor amplified. After a median follow-up of 21 months (range 13–64 months), 9/13 pts without pCR experienced progression disease and 5 of them were dead of SS. At uni- and multivariate analysis, both pCR and downregulation of bcl-2 and Ki67 activity had a significant impact on DFS and OS (p=0.03). Conclusions: 1. Downregulation of bcl-2 and Ki67 index after treatment could be a predictor of recurrence and overall survival. 2. SS is characterized by cellular heterogeneity in which a high proliferative compartment coexists with low proliferative/anti-apoptotic compartment with different response to treatment. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Grisanti
- Spedali Civili di Brescia, Brescia, Italy; University of Brescia, Brescia, Italy; University of Verona, Verona, Italy; Hospital of Treviso, Treviso, Italy
| | - F. Consoli
- Spedali Civili di Brescia, Brescia, Italy; University of Brescia, Brescia, Italy; University of Verona, Verona, Italy; Hospital of Treviso, Treviso, Italy
| | - V. D. Ferrari
- Spedali Civili di Brescia, Brescia, Italy; University of Brescia, Brescia, Italy; University of Verona, Verona, Italy; Hospital of Treviso, Treviso, Italy
| | - L. Bercich
- Spedali Civili di Brescia, Brescia, Italy; University of Brescia, Brescia, Italy; University of Verona, Verona, Italy; Hospital of Treviso, Treviso, Italy
| | - V. Amoroso
- Spedali Civili di Brescia, Brescia, Italy; University of Brescia, Brescia, Italy; University of Verona, Verona, Italy; Hospital of Treviso, Treviso, Italy
| | - G. Rangoni
- Spedali Civili di Brescia, Brescia, Italy; University of Brescia, Brescia, Italy; University of Verona, Verona, Italy; Hospital of Treviso, Treviso, Italy
| | - G. L. Cetto
- Spedali Civili di Brescia, Brescia, Italy; University of Brescia, Brescia, Italy; University of Verona, Verona, Italy; Hospital of Treviso, Treviso, Italy
| | - A. P. Dei Tos
- Spedali Civili di Brescia, Brescia, Italy; University of Brescia, Brescia, Italy; University of Verona, Verona, Italy; Hospital of Treviso, Treviso, Italy
| | - F. Facchetti
- Spedali Civili di Brescia, Brescia, Italy; University of Brescia, Brescia, Italy; University of Verona, Verona, Italy; Hospital of Treviso, Treviso, Italy
| | - G. Marini
- Spedali Civili di Brescia, Brescia, Italy; University of Brescia, Brescia, Italy; University of Verona, Verona, Italy; Hospital of Treviso, Treviso, Italy
| |
Collapse
|
31
|
Viganò M, Lampertico P, Facchetti F, Lunghi G, Colombo M. Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine. J Viral Hepat 2008; 15:922-4. [PMID: 19087228 DOI: 10.1111/j.1365-2893.2008.01047.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Abstract
Nine patients with lamivudine-resistant chronic hepatitis B infection who had been treated with adefovir 10 mg/day and had had a suboptimal response but did not have genotypic resistance to adefovir were treated with high-dose adefovir (20 mg/day). The response to the increased dose of adefovir was compared with the response in 15 patients with a suboptimal response who did not receive an increase in the dose of adefovir. The increase in the dose of adefovir did not lead to a significant reduction in hepatitis B DNA when compared with patients maintained on the standard dose. These data suggest that increasing the dose of adefovir in patients with a suboptimal response does not lead to an improved response.
Collapse
Affiliation(s)
- M Viganò
- A. M. and A. Migliavacca Center for Liver Disease, 1st Division of Gastroenterology, Department of Medicine, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
| | | | | | | | | |
Collapse
|
32
|
Vermi W, Lonardi S, Bosisio D, Uguccioni M, Danelon G, Pileri S, Fletcher C, Sozzani S, Zorzi F, Arrigoni G, Doglioni C, Ponzoni M, Facchetti F. Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma. J Pathol 2008; 216:356-64. [DOI: 10.1002/path.2420] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
33
|
Re A, Ferrari S, Frata P, Pizzocaro C, Crippa C, Tucci A, Facchetti F, Grazioli L, Magrini S, Rossi G. Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study. Ann Oncol 2008; 19:951-7. [DOI: 10.1093/annonc/mdm596] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Manganoni AM, Farisoglio C, Tucci G, Facchetti F, Calzavara Pinton PG. The importance of self-examination in the earliest diagnosis of multiple primary cutaneous melanomas: a report of 47 cases. J Eur Acad Dermatol Venereol 2008; 21:1333-6. [PMID: 17958838 DOI: 10.1111/j.1468-3083.2007.02263.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Development of more than one primary melanoma in a patient is a relatively uncommon but well-recognized phenomenon. Its frequency has ranged from 1.2% to 8.2% in several series. This subgroup of patients with multiple primary lesions has not been characterized sufficiently. We report the experience of the Melanoma Unit of University Hospital Spedali Civili of Brescia, Italy. METHOD Study subjects were drawn from 1240 patients with histologically confirmed melanoma, including melanoma in situ. From this group, multiple melanomas developed in 47 patients (3.79%). Every one of our patients has been taught to perform self-examination of the skin to detect suspicious pigmented lesions. RESULTS Of the 47 patients described in this study, 38 had two primary melanomas, 7 had three melanomas and 2 had 5 and 10 melanomas, respectively. Mean age at first diagnosis was 46.2 years. The majority of subsequent melanomas (74.5%) were removed within 5 years of the initial operation. Synchronous lesions were found in 10 patients. In male patients, the lesion appeared most frequently on the trunk; in female patients, melanoma appeared mostly on the lower extremities. The second primary melanomas developed in the same anatomic region from the first in 53.2% of our patients. The proportion of in situ to invasive melanomas was greater for the second melanomas compared with the first melanomas. Regarding invasive melanomas, the mean thickness of the first melanomas was 1.31 mm compared with 0.66 mm for the second ones. Dividing patients into two groups, of more and less than 50, it is highlighted that in older patients synchronous lesions appear more frequently (36.4% vs. 8.0%); the median time interval between sequential melanomas is longer (84 vs. 63.7 months); and the ratio between the primary and secondary melanoma mean thickness is lower (1.21 : 1.08 vs. 1.43 : 0.63 mm). CONCLUSIONS The study confirms that second primary melanoma is usually thinner than the first lesion, and it is more common in the same region of the body as the initial melanoma. The highest risk for a second melanoma is during the first 5 years, but a much longer time interval of 28 years is possible. Continued medical follow-up with complete skin examinations seems prudent, but it is very important to promote self-skin evaluation in patients to detect not only metastases but also subsequent primary melanomas in their earliest phases.
Collapse
Affiliation(s)
- A M Manganoni
- Department of Dermatology, University Hospital Spedali Civili, Brescia, Italy.
| | | | | | | | | |
Collapse
|
35
|
Tassi RA, Bignotti E, Falchetti M, Ravanini M, Calza S, Ravaggi A, Bandiera E, Facchetti F, Pecorelli S, Santin AD. Claudin-7 expression in human epithelial ovarian cancer. Int J Gynecol Cancer 2008; 18:1262-71. [PMID: 18298564 DOI: 10.1111/j.1525-1438.2008.01194.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Claudin-7 (CLDN-7) is a tight junction protein recently found highly differentially expressed in ovarian carcinoma. To evaluate its potential as a novel biomarker, in this study, we quantified and compared claudin-7 expression at messenger RNA and protein level in 110 patients harboring various histologic types of epithelial ovarian carcinomas (EOC). CLDN-7 transcript was found significantly overexpressed in both primary and metastatic EOCs compared to normal human ovarian surface epithelium cell lines (fold change = 111.4, P < 0.001) by reverse transcription-polymerase chain reaction. At the protein level, CLDN-7 expression was found significantly higher in tumors of primary and metastatic origin when compared to normal ovaries (P < 0.001), regardless of the histologic type, the grade of differentiation, and the pathologic stage of the disease (P = 0.12). Moreover, a strong immunoreactivity for CLDN-7 was detected in EOC cells present in ascites fluids, whereas ascites-derived inflammatory cells, histiocytes, and reactive mesothelial cells were negative. Finally, immunohistochemical expression of CLDN-7 was observed in several human normal epithelial control tissues analyzed. CLDN-7 is significantly overexpressed in all main histologic types of EOC and in single neoplastic cells disseminated in peritoneal cavity and pleural effusions, suggesting its potential role as novel diagnostic marker in ovarian cancer. Despite widespread expression of CLDN-7 in several human normal tissues, the high density of CLDN-7 molecules, their membranous localization on EOC cells, and their lack of expression on the celomic epithelium in the peritoneal cavity suggest that this target could be potentially suitable for antibody-mediated localized therapies of ovarian adenocarcinoma.
Collapse
Affiliation(s)
- R A Tassi
- Division of Gynecologic Oncology, Department of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Manganoni AM, Farisoglio C, Tucci G, Facchetti F, Farfaglia R, Pizzocaro C, Ungari M, Calzavara-Pinton PG. Melanoma patients with melanoma micrometastases in sentinel node that refused completion lymphadenectomy. J Eur Acad Dermatol Venereol 2008; 22:1008-9. [PMID: 18201174 DOI: 10.1111/j.1468-3083.2007.02538.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
Tedoldi S, Mottok A, Ying J, Paterson JC, Cui Y, Facchetti F, van Krieken JHJM, Ponzoni M, Özkal S, Masir N, Natkunam Y, Pileri SA, Hansmann ML, Mason DY, Tao Q, Marafioti T. Selective loss of B-cell phenotype in lymphocyte predominant Hodgkin lymphoma. J Pathol 2007; 213:429-40. [DOI: 10.1002/path.2242] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
38
|
|
39
|
Tecchio C, Nadali G, Scapini P, Bonetto C, Visco C, Tamassia N, Vassilakopoulos TP, Pangalis GA, Calzetti F, Nardelli B, Roschke V, Gottardi M, Zampieri F, Gherlinzoni F, Facchetti F, Pizzolo G, Cassatella MA. High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma. Br J Haematol 2007; 137:553-9. [PMID: 17539776 DOI: 10.1111/j.1365-2141.2007.06615.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
B-lymphocyte stimulator (BLyS) acts as survival factor for B lymphocytes. As Hodgkin and Reed-Sternberg (HRS) cells express receptors through which BLyS promotes their growth and chemotherapy resistance, we investgated whether this molecule was increased in sera from patients with classical Hodgkin lymphoma (cHL) and whether it correlates with clinical-pathological features and outcomes. Enzyme-linked immunosorbent assay was used to measure soluble BLyS (sBLyS) in sera from 87 patients and 33 donors; higher levels were detected in patients (mean +/- standard error 4493.9 +/- 264.9 pg/ml vs. 2687.0 +/- 200.9 pg/ml; P < 0.0001). Levels above the median value (4242.0 pg/ml) were associated with age > or = 45 years (P = 0.042), advanced stages of disease (P = 0.005), systemic symptoms (P = 0.014) and extranodal involvement (P = 0.009). Five-year failure-free survival (FFS) of patients with sBLyS below or equal to median levels was 88.6% as compared to 65.1% of those with levels above the median (P = 0.009). Statistical analyses confirmed the prognostic significance of sBLyS (P = 0.046). When patients were analysed according to variables associated with high levels, sBLyS showed an independent predictive power in terms of FFS. Our findings support the involvement of BLyS in cHL pathogenesis. The association between high serum levels and an inferior FFS indicates that sBLyS is a possible prognostic predictor with a potential significance as a therapeutic target.
Collapse
Affiliation(s)
- C Tecchio
- Section of Haematology, Department of Clinical and Experimental Medicine, Verona University, Verona, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Cassatella MA, Pereira da Silva G, Tinazzi I, Facchetti F, Scapini P, Calzetti F, Tamassia N, Wei P, Nardelli B, Roschke V, Vecchi A, Mantovani A, Bambara LM, Edwards SW, Carletto A. Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis. J Immunol 2007. [DOI: 10.4049/jimmunol.179.2.1390-a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
41
|
Marini G, Grisanti S, Ruggeri G, Ardighieri L, Simoncini E, Amoroso V, Rangoni G, Valcamonico F, Lucini L, Facchetti F. CXCR4/SDF-1 expression in early breast cancer (BC) is not influenced by circulating estrogens serum levels. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.21159] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
21159 Background: The chemokine SDF-1 and its receptor CXCR4 have been found to enhance the metastatic potential of BC cells and correlate with a poorer prognosis of BC patients. Estradiol is a known mitogenic factor for BC cells. SDF-1 has been reported to be an estradiol (E2)-inducible autocrine growth factor that supports the growth of breast cancer cell lines in vitro. The aim of this study was to verify whether estrogens serum levels may influence SDF-1 and CXCR4 expression in vivo, in a series of patients with early stage BC. Methods: 68 patients sequentially observed at the Spedali Civili di Brescia from 2001 to 2002, with a diagnosis of T1a,b,c, N0 breast cancer were retrospectively analysed. CXCR4 and SDF-1 expression was determined by immunohistochemistry with anti-human CXCR4 (Clone 44716) and anti-human SDF-1 (Clone 79018) monoclonal antibodies (R&D Systems, Minneapolis, USA) followed by incubation with the EnVision peroxidase kit (Dakocytomation, Glostrup, Denmark). A serum sample was obtained from all patients at baseline before surgery. Serum estrone (E1) and estradiol (E2) were measured by radioimmunoassay by using commercial kits (Alifax, Padua, IT and Ortho-Clinical Diagnostics, Amersham, UK, respectively). Results: Estrogens serum levels analysis revealed elevated levels of E1 in 9/54 (16%) post-menopausal patients, while E2 levels were in the normal ranges. SDF-1 was expressed in 68/68 (100%) patients with a diffuse and intense cytoplasmatic pattern of staining and CXCR4 was coexpressed in 15/68 (22%) patients with a predominant faint nuclear distibution (p 0,06). No significant correlations were found between CXCR4, SDF-1 and E1 or E2, respectively, as well as with other clinico-pathological characteristics. After a median follow-up of 48 months, 3/68 (4%) patients which all resulted CXC4/SDF1-positive, relapsed and are dead for metastatic disease. Conclusions: This study demonstrates that in T1N0 BC patients: 1) SDF-1 is high levels in the majority of cases; 2) CXCR4 is expressed in approximately 20% of cases with restriction to the nucleus and 3) serum levels of circulating E2 and E1 in pre- or post-menopausal patients, respectively, do not influence CXCR4/SDF-1 expression on breast cancer cells. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- G. Marini
- Spedali Civili, Beretta Foundation, Brescia, Italy; Spedali Civili, University of Brescia, Brescia, Italy
| | - S. Grisanti
- Spedali Civili, Beretta Foundation, Brescia, Italy; Spedali Civili, University of Brescia, Brescia, Italy
| | - G. Ruggeri
- Spedali Civili, Beretta Foundation, Brescia, Italy; Spedali Civili, University of Brescia, Brescia, Italy
| | - L. Ardighieri
- Spedali Civili, Beretta Foundation, Brescia, Italy; Spedali Civili, University of Brescia, Brescia, Italy
| | - E. Simoncini
- Spedali Civili, Beretta Foundation, Brescia, Italy; Spedali Civili, University of Brescia, Brescia, Italy
| | - V. Amoroso
- Spedali Civili, Beretta Foundation, Brescia, Italy; Spedali Civili, University of Brescia, Brescia, Italy
| | - G. Rangoni
- Spedali Civili, Beretta Foundation, Brescia, Italy; Spedali Civili, University of Brescia, Brescia, Italy
| | - F. Valcamonico
- Spedali Civili, Beretta Foundation, Brescia, Italy; Spedali Civili, University of Brescia, Brescia, Italy
| | - L. Lucini
- Spedali Civili, Beretta Foundation, Brescia, Italy; Spedali Civili, University of Brescia, Brescia, Italy
| | - F. Facchetti
- Spedali Civili, Beretta Foundation, Brescia, Italy; Spedali Civili, University of Brescia, Brescia, Italy
| |
Collapse
|
42
|
Grisanti S, Facchetti F, Dei Tos AP, Rossi E, Ardighieri L, Ferrari VD, Amoroso V, Bercich L, Ippolito V, Marini G. Loss of CXCR4 nuclear immunoreactivity in synovial sarcoma (SS) correlates with poor survival. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.10069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10069 Background: The chemokine receptor CXCR4 has been found to be expressed in mesenchymal neoplasms including osteosarcoma, rhabdomyosarcoma, Ewing's sarcoma and SS. Gene products of the HER oncogenic family, such as EGFR and HER2, have been described to be overexpressed in SS and we previously demonstrated coexpression of CXCR4 and EGFR but not HER2 in SS patients. In this study we analysed CXCR4 expression in terms of subcellular localization and extended results to 15 SS patients. Methods: Fifteen SS patients were included in the study. In all cases morphological diagnoses were confirmed molecularly by FISH or RT-PCR specific for t(X;18). HER2 and EGFR expression were determined by immunohistochemistry (IHC) while HER2 gene status was assessed by FISH analysis. CXCR4 expression was determined with an anti-human CXCR4 monoclonal antibody (Clone 44716, R&D Systems, Minneapolis, USA) followed by incubation with the EnVision peroxidase kit (Dakocytomation, Glostrup, Denmark). CXCR4 nuclear vs cytoplasmic expression was correlated with outcome. Results: In all samples IHC analysis for HER2 was negative and no amplification was found by FISH. EGFR expression was observed in 13/15 patients. CXCR4 immunoreactivity was identified in 9/15 cases. CXCR4 and EGFR were coexpressed in 8/15 tumors. Follow-up ranged from 9 to 127 months. After a median follow-up of 39 months, 7 patients were dead of SS, 8 patients were alive (7 of them are disease-free and one has evident disease in the retroperitoneum). All alive and disease-free patients showed nuclear CXCR4 expression whereas 6/7 dead patients expressed cytoplasmic or membrane CXCR4 (p = 0.0008). Conclusions: Loss of nuclear CXCR4 expression is associated with fatal course and may represent a novel prognostic factor. CXCR4 is frequently coexpressed with EGFR but not with HER2. In contrast with previous reports HER2 seems not involved in the carcinogenesis of SS. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Grisanti
- Beretta Foundation, Brescia, Italy; Spedali Civili, Brescia, Italy; Regional Hospital, Treviso, Italy
| | - F. Facchetti
- Beretta Foundation, Brescia, Italy; Spedali Civili, Brescia, Italy; Regional Hospital, Treviso, Italy
| | - A. P. Dei Tos
- Beretta Foundation, Brescia, Italy; Spedali Civili, Brescia, Italy; Regional Hospital, Treviso, Italy
| | - E. Rossi
- Beretta Foundation, Brescia, Italy; Spedali Civili, Brescia, Italy; Regional Hospital, Treviso, Italy
| | - L. Ardighieri
- Beretta Foundation, Brescia, Italy; Spedali Civili, Brescia, Italy; Regional Hospital, Treviso, Italy
| | - V. D. Ferrari
- Beretta Foundation, Brescia, Italy; Spedali Civili, Brescia, Italy; Regional Hospital, Treviso, Italy
| | - V. Amoroso
- Beretta Foundation, Brescia, Italy; Spedali Civili, Brescia, Italy; Regional Hospital, Treviso, Italy
| | - L. Bercich
- Beretta Foundation, Brescia, Italy; Spedali Civili, Brescia, Italy; Regional Hospital, Treviso, Italy
| | - V. Ippolito
- Beretta Foundation, Brescia, Italy; Spedali Civili, Brescia, Italy; Regional Hospital, Treviso, Italy
| | - G. Marini
- Beretta Foundation, Brescia, Italy; Spedali Civili, Brescia, Italy; Regional Hospital, Treviso, Italy
| |
Collapse
|
43
|
Pelizzari A, Drera M, Bellotti D, Marocolo D, Barlati S, Facchetti F, Rossi G. P106 Is cytogenetic follow-up useful in patients with myelodysplastic syndrome? A study of 119 analyses in 79 patients. Leuk Res 2007. [DOI: 10.1016/s0145-2126(07)70176-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
44
|
Poliani PL, Mitola S, Ravanini M, Ferrari-Toninelli G, D'Ippolito C, Notarangelo LD, Bercich L, Wagener C, Memo M, Presta M, Facchetti F. CEACAM1/VEGF cross‐talk during neuroblastic tumour differentiation. J Pathol 2007; 211:541-549. [PMID: 17310502 DOI: 10.1002/path.2135] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The role of angiogenesis in tumour progression is a major subject in modern oncology and a correlation between angiogenesis and poor outcome has been demonstrated for human neuroblastomas. However, the role of angiogenesis in the maturation phase of neuroblastic tumours has never been considered. Human carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), a potent pro-angiogenic factor and mediator of vascular endothelial growth factor (VEGF)-induced angiogenesis, plays a crucial role during the activation phase of angiogenesis and it has been shown to be expressed in the microvessels of the developing central nervous system as well as in newly formed immature blood vessels in many different tumours and under physiological conditions. The present study has investigated the role of CEACAM1/VEGF-mediated angiogenesis across the whole spectrum of neuroblastic tumours, from undifferentiated to fully differentiated mature ganglioneuromas. CEACAM1 is peculiarly expressed in the microvessels of areas of active tumour maturation among differentiating neuroblastic/ganglion cells, whereas it is completely absent in the vessels of poorly differentiated/undifferentiated as well as in entirely mature Schwannian-rich areas. Interestingly, VEGF expression has been found in differentiating neuroblastic/ganglion cells adjacent to CEACAM1-positive microvessels. In keeping with these observations, VEGF expression was found in human neuroblastoma SH-SY5Y cells during differentiation after retinoic acid treatment. Moreover, conditioned medium from SH-SY5Y cells collected at different stages of differentiation induced progressive in vitro up-regulation of CEACAM1 expression in human umbilical vein endothelial cells (HUVECs) that was abrogated by the specific VEGF receptor-2/KDR inhibitor SU5416. Taken together, these data point to a role for CEACAM1/VEGF cross-talk during the maturation phase of neuroblastic tumours. This may mimic physiological events leading to maturation of the vasculature in the developing normal central nervous system. On the other hand, in poorly differentiated/undifferentiated lesions, VEGF-sustained angiogenesis does not reproduce physiological steps, but rather is associated with tumour aggressiveness and may involve other molecular pathways.
Collapse
Affiliation(s)
- P L Poliani
- Department of Pathology, University of Brescia, Brescia, Italy
| | - S Mitola
- Unit of General Pathology and Immunology, Department of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy
| | - M Ravanini
- Department of Pathology, University of Brescia, Brescia, Italy
| | - G Ferrari-Toninelli
- Unit of Pharmacology, Department of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy
| | - C D'Ippolito
- Department of Paediatrics, University of Brescia, Brescia, Italy
| | - L D Notarangelo
- Department of Paediatrics, University of Brescia, Brescia, Italy
| | - L Bercich
- Department of Pathology, University of Brescia, Brescia, Italy
| | - C Wagener
- Department of Clinical Chemistry, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - M Memo
- Unit of Pharmacology, Department of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy
| | - M Presta
- Unit of General Pathology and Immunology, Department of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy
| | - F Facchetti
- Department of Pathology, University of Brescia, Brescia, Italy
| |
Collapse
|
45
|
Re A, Facchetti F, Borlenghi E, Cattaneo C, Capucci MA, Ungari M, Barozzi P, Vallerini D, Potenza L, Torelli G, Rossi G, Luppi M. Fatal hemophagocytic syndrome related to active human herpesvirus-8/Kaposi sarcoma-associated herpesvirus infection in human immunodeficiency virus-negative, non-transplant patients without related malignancies. Eur J Haematol 2007; 78:361-4. [PMID: 17331129 DOI: 10.1111/j.1600-0609.2007.00828.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Hemophagocytic syndrome (HS) may occur as a consequence of herpes viral infections. Human herpesvirus 8 (HHV-8)/Kaposi sarcoma-associated herpesvirus has so far been recognized as a trigger of HS only in immunosuppressed subjects or in patients with Kaposi sarcoma and/or HHV-8-related lymphoproliferative diseases. We report two Italian human immunodeficiency virus (HIV)-negative elderly men who developed an HS with a rapidly fatal course, following treatment with corticosteroids for autoimmune hemolytic anemia. An overwhelming active infection with HHV-8 was unequivocally documented by molecular and immunohistochemical methods, in the absence of HHV-8-related tumors. The occurrence of HHV-8-associated HS, although rare, may be considered, even out of the HIV or the transplantation settings, at least in areas endemic for HHV-8 infection.
Collapse
MESH Headings
- Adrenal Cortex Hormones/therapeutic use
- Aged
- Anemia, Hemolytic, Autoimmune/complications
- Anemia, Hemolytic, Autoimmune/diagnosis
- Anemia, Hemolytic, Autoimmune/drug therapy
- Fatal Outcome
- Female
- Herpesviridae Infections/complications
- Herpesviridae Infections/diagnosis
- Herpesvirus 8, Human/isolation & purification
- Humans
- Kidney Neoplasms/complications
- Kidney Neoplasms/surgery
- Lymphohistiocytosis, Hemophagocytic/diagnosis
- Lymphohistiocytosis, Hemophagocytic/drug therapy
- Lymphohistiocytosis, Hemophagocytic/virology
- Male
- Middle Aged
Collapse
Affiliation(s)
- A Re
- Division of Hematology, Spedali Civili di Brescia, Brescia, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
La Porta CAM, Cardano R, Facchetti F, Presicce P, Rao S, Privitera E, Clemente C, Mihm MC. BRAF V599E mutation occurs in Spitz and Reed naevi. J Eur Acad Dermatol Venereol 2007; 20:1164-5. [PMID: 16987295 DOI: 10.1111/j.1468-3083.2006.01665.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
47
|
Tedoldi S, Paterson JC, Cordell J, Tan SY, Jones M, Manek S, Dei Tos AP, Roberton H, Masir N, Natkunam Y, Pileri SA, Facchetti F, Hansmann ML, Mason DY, Marafioti T. Jaw1/LRMP, a germinal centre-associated marker for the immunohistological study of B-cell lymphomas. J Pathol 2006; 209:454-63. [PMID: 16739114 DOI: 10.1002/path.2002] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Jaw1, also known as lymphoid-restricted membrane protein (LRMP), is an endoplasmic reticulum-associated protein. High levels of Jaw1/LRMP mRNA have been found in germinal centre B-cells and in diffuse large B-cell lymphomas of 'germinal centre' subtype. This paper documents Jaw1/LRMP expression at the protein level in human tissues by immunohistochemical and western blotting analysis using an antibody reactive with paraffin-embedded tissues. Jaw1/LRMP was highly expressed in germinal centre B-cells (in keeping with gene expression data), in 'monocytoid B-cells', and in splenic marginal zone B-cells. It was absent, or present at only low levels, in mature T-cells, although cortical thymocytes were weakly positive. Among lymphoid neoplasms, Jaw1/LRMP was found in germinal centre-derived lymphomas (follicle centre lymphoma, Burkitt's lymphoma, lymphocyte-predominant Hodgkin's disease) but not in T-cell neoplasms (with the exception of a single T lymphoblastic lymphoma). Classical Hodgkin's disease and myeloma lacked Jaw1/LRMP but many cases of chronic lymphocytic leukaemia (but not mantle zone lymphoma) were Jaw1/LRMP-positive. Approximately half of the marginal zone lymphomas were Jaw1/LRMP-positive. In diffuse large B-cell lymphomas, Jaw1/LRMP was found in three-quarters (24/32) of the cases classified phenotypically as being of 'germinal centre' type, but it was also expressed in almost half (13/28) of the 'non-germinal centre' cases. A similar proportion of 'non-germinal centre' cases were positive for the protein products of two other genes expressed highly in germinal centre cells (HGAL/GCET2 and PAG). The fact that all three of these proteins are expressed in a significant proportion of diffuse large B-cell lymphomas assigned to the 'non-germinal centre' category indicates that the immunophenotypic categorization of diffuse large B-cell lymphoma according to cellular origin may be more complicated than currently understood. Finally, the expression of Jaw1/LRMP in other types of lymphoma and in non-lymphoid tissues/tumours may be of interest in differential diagnosis and research.
Collapse
Affiliation(s)
- S Tedoldi
- Leukaemia Research Fund Immunodiagnostics Unit, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Grisanti S, Rossi E, Ardighieri L, Farisoglio C, Ferrari VD, Bercich L, Simoncini E, Marini G, Facchetti F. CXCR4, EGFR and HER2 expression in patients with high-risk synovial sarcoma (SS): A clinicopathologic study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.9580] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9580 Background: CXCR4 is overexpressed in many human tumors and plays important role in targeted metastasis. CXCR4 activation has been described in osteosarcoma, rhabdomyosarcoma and Ewing’s sarcoma both in vivo and in vitro, but its role has not been elucidated in SS yet. EGFR and Her2/neu, have been described to be overexpressed in patients with SS and proposed as potential therapeutic targets. Because CXCR4 and Her2 have been found to be functionally linked in breast cancer cell lines, we characterized SS in terms of CXCR4, Her2 and EGFR coexpression. Materials and Methods: Six patients sequentially observed at the Spedali Civili di Brescia from 1999 to 2005, with a diagnosis of synovial sarcoma were included in the study. The diagnosis of SS, a FISH analysis for t(X;18) was performed by using a commercial probe specific for the SYT gene breakpoint region (18q11) or by RT-PCR. Her2 and EGFR expression were determined by IHC and Her2 gene amplification by FISH analysis. CXCR4 expression was determined by IHC with anti-human CXCR4 monoclonal antibody (Clone 44716, R&D Systems) followed by incubation with the EnVision peroxidase kit (Dakocytomation, Glostrup, Denmark). Results: All patients were classified high-risk (stage III-IV) according to the AJCC/UICC VI Edition Staging System for soft tissue sarcomas. In all samples IHC analysis for Her2 was negative and no amplification was found by FISH. EGFR staining demonstrated positivity in 5 patients out of 6. CXCR4 reactivity was identified in 4 cases (nuclear staining in 3 and membrane staining in 1). CXCR4 and EGFR were coexpressed in 3 tumors. After a median follow-up of 24 months, 2 patients are dead of SS, 4 patients are alive, 3 of them are disease-free and one relapsed to the lung. The 3 patients alive and disease-free resulted positive for nuclear CXCR4 and EGFR while membrane CXCR4 was expressed in one dead patient. Conclusion: This study provides evidence that CXCR4 is expressed in cases of SS and is frequently coexpressed with EGFR but not with Her2. Due to the small size of this series it is not possible to establish any definitive prognostic or predictive value of CXCR4. However, nuclear expression of CXCR4 seems to be associated with a more indolent behaviour of the tumor and requires confirmation in larger series. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Grisanti
- Unità di Oncologia Medica & Fondazione Beretta, Brescia, Italy; II Servizio di Anatomia e Istologia Patologica, Spedali Civili & Università degli Studi, Brescia, Italy; I Servizio di Anatomia e Istologia Patologica, Spedali Civili & Università degli Studi, Brescia, Italy
| | - E. Rossi
- Unità di Oncologia Medica & Fondazione Beretta, Brescia, Italy; II Servizio di Anatomia e Istologia Patologica, Spedali Civili & Università degli Studi, Brescia, Italy; I Servizio di Anatomia e Istologia Patologica, Spedali Civili & Università degli Studi, Brescia, Italy
| | - L. Ardighieri
- Unità di Oncologia Medica & Fondazione Beretta, Brescia, Italy; II Servizio di Anatomia e Istologia Patologica, Spedali Civili & Università degli Studi, Brescia, Italy; I Servizio di Anatomia e Istologia Patologica, Spedali Civili & Università degli Studi, Brescia, Italy
| | - C. Farisoglio
- Unità di Oncologia Medica & Fondazione Beretta, Brescia, Italy; II Servizio di Anatomia e Istologia Patologica, Spedali Civili & Università degli Studi, Brescia, Italy; I Servizio di Anatomia e Istologia Patologica, Spedali Civili & Università degli Studi, Brescia, Italy
| | - V. D. Ferrari
- Unità di Oncologia Medica & Fondazione Beretta, Brescia, Italy; II Servizio di Anatomia e Istologia Patologica, Spedali Civili & Università degli Studi, Brescia, Italy; I Servizio di Anatomia e Istologia Patologica, Spedali Civili & Università degli Studi, Brescia, Italy
| | - L. Bercich
- Unità di Oncologia Medica & Fondazione Beretta, Brescia, Italy; II Servizio di Anatomia e Istologia Patologica, Spedali Civili & Università degli Studi, Brescia, Italy; I Servizio di Anatomia e Istologia Patologica, Spedali Civili & Università degli Studi, Brescia, Italy
| | - E. Simoncini
- Unità di Oncologia Medica & Fondazione Beretta, Brescia, Italy; II Servizio di Anatomia e Istologia Patologica, Spedali Civili & Università degli Studi, Brescia, Italy; I Servizio di Anatomia e Istologia Patologica, Spedali Civili & Università degli Studi, Brescia, Italy
| | - G. Marini
- Unità di Oncologia Medica & Fondazione Beretta, Brescia, Italy; II Servizio di Anatomia e Istologia Patologica, Spedali Civili & Università degli Studi, Brescia, Italy; I Servizio di Anatomia e Istologia Patologica, Spedali Civili & Università degli Studi, Brescia, Italy
| | - F. Facchetti
- Unità di Oncologia Medica & Fondazione Beretta, Brescia, Italy; II Servizio di Anatomia e Istologia Patologica, Spedali Civili & Università degli Studi, Brescia, Italy; I Servizio di Anatomia e Istologia Patologica, Spedali Civili & Università degli Studi, Brescia, Italy
| |
Collapse
|
49
|
Abstract
The cancer stem cell hypothesis suggests that neoplastic clones are maintained exclusively by a rare fraction of cells with stem cell proprieties. Stem cells are defined as cells which are able to both extensively self-renew and differentiate into progenitors. Furthermore, stem cells are also attractive candidates as origin of cancers, as in their long lifespan mutations and epigenetic changes they can increase allowing for increasing evolution toward malignancy. Herein, we discuss the evidences reported in literature on existence of cancer stem cells in several tumors and mechanisms of the extrinsic and intrinsic circuitry controlling stem cell fate as well as their possible connections to cancer. In particular, the review will focus on recent results on conserved Polycomb Group (PcG) gene family, an epigenetic chromatin modifiers involved in cancer development and also in the maintenance of embryonic and adult stem cells. There are two distinct multiprotein PcG complexes identified, Polycomb repressive complex (PRC) 1 and 2. The fact that either PRC1 Bmi1 than PRC2 SU(Z)12 components are implicated in self-renewal stem cells and up-regulated in several kind of human cancer, confirm the importance of (de)regulation of the PcG genes in cancer and stem cell biology. Moreover, Bmi1 and SU(Z)12 are downstream target of Sonic hedgehog (Shh) and Wnt signaling respectively, providing for a connection between epigenetic change regulators (PcG) and developmental-signaling pathways. Finally, potential therapies using inhibitors acting on cancer stem cell population such as cyclopamine, an inhibitor of hedgehog signalling, 6-bromoindirubin-3'-oxime (BIO) which acts on GSK3 and inhibitors of beta-catenin signaling such as exisulind and the tyrosine-kinase inhibitor STI571/Gleevac/imatinib will also discuss.
Collapse
Affiliation(s)
- E Galmozzi
- Department of Biomolecular Science and Biotechnology, University of Milan, Italy
| | | | | |
Collapse
|
50
|
Paulli M, Artusi T, Baroni CD, Carbone A, Coggi G, Di Lollo S, Facchetti F, Falini B, Franco V, Gambacorta M, La Rocca VM, Leoncini L, Magrini U, Maiorana A, Menestrina F, Novero D, Palestro G, Pescarmona E, Santucci M, Stracca Pansa V, Truini M, Pileri S. [The Haemolymphopathology Italian Group (H.I.G.): an essential resource for the new technical and organization problems troubling modern haemolymphopathology diagnostics]. Pathologica 2006; 98:37-40. [PMID: 16789684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/10/2023] Open
Abstract
Recently, many progresses have been recorded in the molecular and histogenetic characterization of the haematopoietic and lymphoid tumours, resulting in important classifying changes. As a consequence, the exact definition of lymphoma subtype requires an integration between traditional morphologic "expertise" and several bio-functional data obtained from advanced and complex ancillary techniques (immunohistochemistry, molecular biology and cytogenetics). At the same time, the data provided by gene expression profiling studies are going to deeply modify the therapies in haematological cancers. These studies are expected to allow the achievement of single-patient-tailored genic therapy; for this reason it is necessary to get biological samples of good quality. Indeed, while these progresses contribute to highlight the pathologist's diagnostic role, they should make us reflect on the state of the art of the Italian haemolymphopathology diagnostics and on its ability to cope up with the new challanges. The aim of this article is to outline a realistic picture of the present condition, and to explain the reasons for setting up, inside SIAPEC-IAP, the Haemolymphopathology Italian Group (H.I.G.). The purpose of H.I.G. will be twofold: first of all, scheduling of a series of projects so as to the haemolymphopathological diagnostic standardization; secondly, building a national network among all the pathologists involved in this exciting and complex field of the anatomic pathology.
Collapse
Affiliation(s)
- M Paulli
- Sezione di Anatomia Patologica, Dipartimento di Patologia Umana ed Ereditaria, I.R.C.C.S. Policlinico S. Matteo, Universita di Pavia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|